Malavika Vinta, MD | |
408 W 45th St, Austin, TX 78751-3014 | |
(512) 451-5800 | |
(512) 459-1399 |
Full Name | Malavika Vinta |
---|---|
Gender | Female |
Speciality | Nephrology |
Experience | 23 Years |
Location | 408 W 45th St, Austin, Texas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518903525 | NPI | - | NPPES |
166322104 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RN0300X | Internal Medicine - Nephrology | L9536 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hill Country Dialysis | Kyle, TX | Dialysis facility |
South Austin Dialysis Llc | Austin, TX | Dialysis facility |
St David's Medical Center | Austin, TX | Hospital |
Ascension Seton Medical Center Austin | Austin, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Austin Kidney Associates, P. A. | 1658511217 | 32 |
News Archive
With a new insight into a model of Parkinson's disease, researchers from the University of Pennsylvania School of Veterinary Medicine have identified a novel target for mitigating some of the disease's toll on the brain.
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.
XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.
› Verified 1 days ago
Entity Name | Shannon Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1770587149 PECOS PAC ID: 0840103727 Enrollment ID: O20031222000702 |
News Archive
With a new insight into a model of Parkinson's disease, researchers from the University of Pennsylvania School of Veterinary Medicine have identified a novel target for mitigating some of the disease's toll on the brain.
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.
XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.
› Verified 1 days ago
Entity Name | Austin Kidney Associates, P. A. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1154669331 PECOS PAC ID: 1658511217 Enrollment ID: O20130703000239 |
News Archive
With a new insight into a model of Parkinson's disease, researchers from the University of Pennsylvania School of Veterinary Medicine have identified a novel target for mitigating some of the disease's toll on the brain.
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.
XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Malavika Vinta, MD 408 W 45th St, Austin, TX 78751 Ph: (512) 451-5800 | Malavika Vinta, MD 408 W 45th St, Austin, TX 78751-3014 Ph: (512) 451-5800 |
News Archive
With a new insight into a model of Parkinson's disease, researchers from the University of Pennsylvania School of Veterinary Medicine have identified a novel target for mitigating some of the disease's toll on the brain.
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.
XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.
› Verified 1 days ago
Dr. Tatiana B. Jacobson, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd. Bldg C Ste. 102, Austin, TX 78746 Phone: 512-323-5465 Fax: 512-327-1390 | |
Preeti Venkatraman, M.B.B.S. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-7000 | |
Pritesh Harish Gandhi, M.D., M.P.H. Nephrology Medicare: Medicare Enrolled Practice Location: 1101 Camino La Costa, Austin, TX 78752 Phone: 512-684-1832 | |
Dr. Joshua Lane Davis, D.O. Nephrology Medicare: Medicare Enrolled Practice Location: 1004 W 32nd St Unit 300, Austin, TX 78705 Phone: 512-324-3440 | |
Dr. Analicia Alvarado, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-324-7000 | |
Dr. Grace Marie Grant-jennings, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 7000 North Mopac, Suite # 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Dr. Debra Ann Patt, MD, MPH Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6204 Balcones Dr, Austin, TX 78731 Phone: 512-427-9400 Fax: 512-342-2723 |